Seqirus USA Inc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$65.6M
Doctors Paid
15,410
Transactions
57,789
2024 Total
$16.7M
Payment Breakdown by Category
Research$64.2M (97.8%)
Food & Beverage$454,056 (0.7%)
Consulting$403,062 (0.6%)
Travel$142,101 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $64.2M | 34,300 | 97.8% |
| Food and Beverage | $454,056 | 22,586 | 0.7% |
| Consulting Fee | $403,062 | 161 | 0.6% |
| Honoraria | $287,607 | 128 | 0.4% |
| Travel and Lodging | $142,101 | 180 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $108,605 | 29 | 0.2% |
| Grant | $20,000 | 1 | 0.0% |
| Education | $8,712 | 404 | 0.0% |
Payments by Type
Research
$64.2M
34,300 transactions
General
$1.4M
23,489 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | $14.9M | 0 | 12,030 |
| A Study to Evaluate Safety Immunogenicity and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects greater than or equal to 18 Years of Age | $6.9M | 0 | 208 |
| A Phase 2b, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Confirmation Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age | $6.9M | 0 | 12,551 |
| Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/?or H5N6 Influenza Vaccine in Adults | $5.6M | 0 | 220 |
| A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Comparison With a Licensed Quadrivalent Influenza Vaccine, in Adults 50 to 64 Years of Age | $5.5M | 0 | 228 |
| A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months | $3.7M | 0 | 153 |
| Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects | $3.5M | 1 | 492 |
| A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age | $3.0M | 0 | 341 |
| A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. | $2.4M | 0 | 4,594 |
| Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults | $2.4M | 0 | 52 |
| Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults | $2.3M | 2 | 2,659 |
| Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults | $2.3M | 2 | 333 |
| Adjuvanted influenza Vaccination and Morbidity and Mortaliy in US Nursing Homes | $2.1M | 0 | 8 |
| A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects 18 Years of Age | $1.3M | 0 | 86 |
| This phase 3 study is a randomized, double-blinded, comparator controlled, parallel-group, multicenter study of aQIV versus the US-licensed 2017-2018 adjuvanted trivalent influenza vaccine aTIV-1, Fluad, and versus an adjuvanted trivalent influenza vaccine aTIV-2, containing the alternate B strain | $1.0M | 0 | 103 |
| A Phase 2/3 Randomised, Observer-blind, Placebo-controlled, Multi-centre Study to Evaluate the Efficacy, Immunogenicity and Safety of the Adjuvanted SARS-CoV-2 Subunit Vaccine in Adults Aged 18 Years and Above | $137,740 | 0 | 31 |
| A PHASE 3 RANDOMIZED, OBSERVER-BLIND, MULTI-CENTER, CONTROLLED STUDY TO EVALUATE SAFETY, IMMUNOGENICITY, AND LOT-TO-LOT CONSISTENCY OF AN ADJUVANTED CELL CULTURE-DERIVED, H5N1 SUBUNIT INFLUENZA VIRUS VACCINE IN HEALTHY ADULT SUBJECTS 18 YEARS OF AGE | $83,437 | 0 | 9 |
| A Phase III, Randomized, Observer-blind, Multicenter, Non-inferiority Study To Evaluate The Immunogenicity And Safety Of Seqirus QIVc and a Licensed QIV Comparator Vaccine in Healthy Subjects 6 Months Through 47 Months of Age | $47,968 | 0 | 14 |
| A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above | $30,082 | 0 | 6 |
| A Prospective Observational Safety Study on Pregnancy Outcomes in Women Immunized With Seasonal Cell Culture Influenza Trivalent TIVc or Quadrivalent QIVc Vaccine During Pregnancy | $30,063 | 0 | 2 |
| Vdg_Test Negative Study | $26,025 | 3 | 12 |
| A Phase III Randomized Observer-Blind Controlled Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults greater than or equal to 65 Years of Age | $16,000 | 0 | 8 |
| V13010 is A Phase III, Randomized, Observer-blind, Multicenter, Non-inferiority Study To Evaluate The Immunogenicity And Safety Of Seqirus QIVc and a Licensed QIV Comparator Vaccine in Healthy Subjects 6 Months Through 47 Months of Age | $10,200 | 0 | 2 |
| A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults 65 Years of Age | $9,600 | 0 | 6 |
| Clinical Study to Evaluate the Safety Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children | $8,417 | 1 | 127 |
| A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages 18 Years of Age | $8,000 | 0 | 2 |
| This is a study to assess the immune antibody response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine Seqirus QIV, in comparison with a US licensed 20162017 Quadrivalent Influenza Vaccine comparator QIV in a healthy pediatric population 6 months through 59 months of age. | $7,270 | 0 | 3 |
| Efficacy Study With QIVc in Pediatric Subjects | $6,625 | 1 | 5 |
| Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of Three Investigational Self-Amplifying Mrna/Lnp Influenza Virus Vaccines In Healthy Adults | $6,525 | 1 | 6 |
| Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects 2 to <18 Years of Age | $4,625 | 1 | 5 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Unknown Provider | — | — | $10,444 | $0 |
| Manoj Aswani, M.d, M.D | Internal Medicine | Thousand Oaks, CA | $9,800 | $0 |
| Dr. Justin Ortiz, M.d, M.D | Critical Care Medicine | Baltimore, MD | $9,363 | $0 |
| Dr. Stanley Plotkin, Md, MD | Clinical & Laboratory Immunology | Doylestown, PA | $9,344 | $0 |
| Victoria Statler, M.d, M.D | Pediatrics | Louisville, KY | $9,300 | $0 |
| Carol Baker, Md, MD | Pediatric Infectious Diseases | Houston, TX | $9,105 | $0 |
| Echezona Ezeanolue, M.d, M.D | Pediatric Infectious Diseases | Las Vegas, NV | $9,076 | $0 |
| Stefan Gravenstein, Md, MD | Geriatric Medicine | Providence, RI | $8,937 | $0 |
| Mrs. Yvonne Dsouza, Md, MD | Internal Medicine | Bronx, NY | $8,225 | $0 |
| Ann-Christine Nyquist, Md, MD | Pediatric Infectious Diseases | Aurora, CO | $8,018 | $0 |
| Dr. Peter Shalit, M.d, M.D | Internal Medicine | Seattle, WA | $8,000 | $0 |
| Darvin Smith | Infectious Disease | Redwood City, CA | $7,957 | $0 |
| Peter Patriarca, M.d, M.D | Contractor | Bethesda, MD | $7,789 | $0 |
| Dr. Kelly Moore, M.d., Mph, M.D., MPH | Public Health & General Preventive Medicine | Nashville, TN | $7,593 | $0 |
| John Treanor, Md, MD | Infectious Disease | Rochester, NY | $7,134 | $0 |
| Ruth Carrico, Rn, Msn, Phd, RN, MSN, PHD | Family | Louisville, KY | $6,990 | $0 |
| Robert Frenck, Md, MD | Pediatric Infectious Diseases | Cincinnati, OH | $6,748 | $0 |
| Dr. John Vanchiere, Md/Phd, MD/PHD | Pediatric Infectious Diseases | Shreveport, LA | $6,650 | $0 |
| Dr. Mobeen Rathore, M.d, M.D | Pediatrics | Jacksonville, FL | $6,456 | $0 |
| Amesh Adalja, Md, MD | Emergency Medicine | Pittsburgh, PA | $6,029 | $0 |
| David Weber, Md, MD | Pediatric Infectious Diseases | Chapel Hill, NC | $6,000 | $0 |
| Paul Hunter, Md, MD | Adult Medicine | Madison, WI | $5,513 | $0 |
| Natasha Halasa, Md, MD | Pediatric Infectious Diseases | Nashville, TN | $5,189 | $0 |
| Dr. Randall Hyer, M.d., Ph.d., M.p.h, M.D., PH.D., M.P.H | Public Health & General Preventive Medicine | Lower Gwynedd, PA | $5,000 | $0 |
| Prof. Nadine Rouphael, M.d, M.D | Infectious Disease | Atlanta, GA | $4,892 | $0 |
Ad
Top Products
- aH5N1c $4.4M
- Flucelvax $4.1M
Associated Products (10)
- aH5N1c $4.4M
- Flucelvax $4.1M
- QIV $3.0M
- Fluad $2.8M
- H5N1c $2.5M
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) $689,829
- FLUCELVAX QUADRIVALENT $388,788
- Fluvirin $267,310
- Fluad Quadrivalent $218,454
- aQIV $15,217
Payment Categories
- Food & Beverage $454,056
- Consulting $403,062
- Travel & Lodging $142,101
- Research $64.2M
About Seqirus USA Inc
Seqirus USA Inc has made $65.6M in payments to 15,410 healthcare providers, recorded across 57,789 transactions in the CMS Open Payments database. In 2024, the company paid $16.7M. The top product by payment volume is aH5N1c ($4.4M).
Payments were distributed across 164 medical specialties. The top specialty by payment amount is Pediatrics ($495,563 to 4,992 doctors).
Payment categories include: Food & Beverage ($454,056), Consulting ($403,062), Research ($64.2M), Travel & Lodging ($142,101).
Seqirus USA Inc is associated with 10 products in the CMS Open Payments database, including aH5N1c, Flucelvax, and QIV.